CHARM Therapeutics
London · Founded 2021 · 31 employees on LinkedIn · 6 known investors
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.
Founders & leadership
CHARM Therapeutics was founded in 2021 by Lakshyaditya Singh Aithani.
LS
Lakshyaditya Singh AithaniFounder
Board
RG
Rishi GuptaBoard director
NS
MM
Muzammil MansuriBoard director
GG
Gary GlickBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$87M disclosed across 4 rounds · 2021–2025
▶$17.3MraisedSep 2025 · 20 investors · OtherRule 506(b)
▶$17.3MraisedSep 2025 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Gary GlickExecutive Officer, Director, Promoter
- Mahesh KudariDirector
- Briggs MorrisonDirector
- Nihal SinhaDirector
- Kim BlackwellDirector
- Matthew McAvineyDirector
- Rishi GuptaDirector
- Offering amount
- $80.1M
- Amount sold
- $17.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$20MraisedApr 2023 · 2 investors · OtherRule 506(b)
▶$20MraisedApr 2023 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Gary GlickDirector
- Lakshyaditya Singh AithaniExecutive Officer, Director
- Nihal SinhaDirector
- Muzammil MansuriDirector
- Rishi GuptaDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$37MraisedJun 2022 · 18 investors · Other Health CareRule 506(b)
▶$37MraisedJun 2022 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gary GlickDirector
- Rishi GuptaDirector
- Nihal SinhaDirector
- Lakshyaditya Singh AithaniExecutive Officer, Director
- Muzammil MansuriDirector
- Offering amount
- $37M
- Amount sold
- $37M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$12.6MraisedOct 2021 · 8 investors · Other Health CareRule 506(b)
▶$12.6MraisedOct 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lakshyaditya Singh AithaniExecutive Officer, Director, Promoter
- Offering amount
- $13.5M
- Amount sold
- $12.6M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does CHARM Therapeutics do?
- CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.
- Who founded CHARM Therapeutics?
- CHARM Therapeutics was founded by Lakshyaditya Singh Aithani in 2021.
- Who are CHARM Therapeutics's investors?
- CHARM Therapeutics's investors include F-Prime Capital, New Enterprise Associates (NEA), OrbiMed, SR One Capital Management, Axial VC, NVentures.
- How much funding has CHARM Therapeutics raised?
- CHARM Therapeutics has disclosed $87M raised across 4 rounds.
- Where is CHARM Therapeutics headquartered?
- CHARM Therapeutics is headquartered in London.